DRL-17822 | 1454689-50-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: DRL-17822
• 英文别名: 2-(Bis(cyclopropylmethyl)amino)-N-((3,5-bis(trifluoromethyl)phenyl)methyl)-8-methyl-N-(2-methyl-2H-tetrazol-5-yl)-3-quinolinemethanamine；3-[[[3,5-bis(trifluoromethyl)phenyl]methyl-(2-methyltetrazol-5-yl)amino]methyl]-N,N-bis(cyclopropylmethyl)-8-methylquinolin-2-amine
• CAS: 1454689-50-9；898911-09-6
• 化学式: C₃₀H₃₁F₆N₇
• 分子量: 603.613
• InChiKey: OCNBSSLDAIWTKS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.9
• 重原子数：
  43
• 可旋转键数：
  10
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  63
• 氢给体数：
  0
• 氢受体数：
  12

文献信息

• Novel benzylamine derivatives and their utility as cholesterol ester-transfer protein inhibitors
  申请人：Baruah Anima

  公开号：US20070015758A1

  公开（公告）日：2007-01-18

  The present invention provides, among other things, new benzylamine compounds, compositions comprising benzylamine compounds, methods of making benzylamine compounds, and methods of using benzylamine compounds for treating or preventing a variety of conditions or diseases associated with lipoprotein metabolism.

  本发明提供了新的苄基胺化合物，包括苄基胺化合物的组合物，制备苄基胺化合物的方法，以及使用苄基胺化合物治疗或预防与脂蛋白代谢有关的各种疾病或症状的方法。
• SUBSTITUTED BENZYLAMINO QUINOLINES AS CHOLESTEROL ESTER-TRANSFER PROTEIN INHIBITORS
  申请人：DR. REDDY'S LABORATORIES LTD.

  公开号：US20150216866A1

  公开（公告）日：2015-08-06

  The present invention provides a method for treating or preventing a condition or disease in a human or an animal subject wherein the condition or disease is associated with lipoprotein metabolism, the method comprising administering to the subject a composition comprising benzylamine compounds.

  本发明提供了一种治疗或预防与脂蛋白代谢有关的人类或动物主体的疾病或状况的方法，该方法包括向该主体给予含有苄胺化合物的组合物。
• NOVEL BENZYLAMINE DERIVATIVES AND THEIR UTILITY AS CHOLESTEROL ESTER-TRANSFER PROTEIN INHIBITORS
  申请人：DR. REDDY'S LABORATORIES LTD.

  公开号：US20140134235A1

  公开（公告）日：2014-05-15

  The present invention provides, among other things, new benzylamine compounds, compositions comprising benzylamine compounds, methods of making benzylamine compounds, and methods of using benzylamine compounds for treating or preventing a variety of conditions or diseases associated with lipoprotein metabolism.

  本发明提供了新的苄基胺化合物，包括苄基胺化合物的组合物，制备苄基胺化合物的方法，以及使用苄基胺化合物治疗或预防与脂蛋白代谢有关的各种疾病或症状的方法。
• NOVEL BENZYLAMINE DERIVATIVES AS CETP INHIBITORS
  申请人：Dr. Reddy's Laboratories Ltd.

  公开号：EP1848430B1

  公开（公告）日：2017-08-02
• PHARMACEUTICAL COMPOSITIONS OF CETP INHIBITORS
  申请人：Dr. Reddy's Laboratories Ltd.

  公开号：EP2919765A2

  公开（公告）日：2015-09-23